ProShares Ultra NASDAQ Biotechnology
27 hedge funds and large institutions have $15.6M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.85% less ownership
Funds ownership: 7.29% → 6.43% (-0.85%)
3% less capital invested
Capital invested by funds: $16.2M → $15.6M (-$528K)
31% less call options, than puts
Call options by funds: $8.63M | Put options by funds: $12.5M
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$973K |
| 2 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
+$273K |
| 3 |
Koshinski Asset Management
Decatur,
Illinois
|
+$247K |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$31K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.42M |
| 2 |
VF
Virtu Financial
New York
|
-$1.52M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.29M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$895K |
| 5 |
Morgan Stanley
New York
|
-$63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Koshinski Asset Management
Decatur,
Illinois
| $254 | +$247K | +4,587 | New |
|
|
VF
27
Virtu Financial
New York
| – | -$1.52M | -36,142 | Closed |
|
28
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$42K | -1,000 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$27K | -642 | Closed |
|
|
CG
30
Cutler Group
San Francisco,
California
| – | -$21.5K | -399 | Closed |
|
|
IA
31
IFP Advisors
Tampa,
Florida
| – | -$7K | -175 | Closed |
|
BIB Hedge Fund Activity: Q1 2019 in Review
27 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2019, worth a combined $15.6M — down 3.3% from $16.2M a quarter earlier.
Fund positioning in BIB was balanced in Q1 2019: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 7 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $973K. The largest seller was Susquehanna International Group, cutting an estimated $2.42M.
- 27 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $15.6M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2019, down 3.3% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2019 and 5 closed out, a net change of 0 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2019 was Jane Street, an estimated $973K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2019 was Susquehanna International Group, an estimated $2.42M sold.
Based on aggregated 13F filings for Q1 2019.